A restrictive stoma policy after colorectal anastomosis in ovarian cancer based on ghost ileostomy use.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
11 Apr 2024
Historique:
received: 08 02 2024
revised: 31 03 2024
accepted: 06 04 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 18 4 2024
Statut: aheadofprint

Résumé

The incidence of anastomotic leak after colorectal anastomosis in ovarian cancer has been reported to be much lower than that in colorectal cancer patients. Regarding the use of protective manoeuvres (diverting ileostomy) as suggested by clinical guidelines, the goal should be the implementation of a restrictive stoma policy for ovarian cancer patients, given the low rate of anastomotic leakage in this population. Patients who underwent cytoreduction surgery in a single centre (University Hospital La Fe, Valencia Spain) due to ovarian cancer between January 2010 and June 2023 were classified according to two groups: a non-restrictive stoma policy group (Group A) and a restrictive stoma policy group (Group B). A total of 256 patients were included in the analysis (group A 52 % vs group B 48 %). The use of protective diverting ileostomy was lower in the restrictive stoma policy group (14 % vs 6.6 %), and the use of ghost ileostomy was 32 % vs 87 % in groups A and B, respectively (p < 0.00001). No differences were found in the anastomotic leak rate, which was 5.2 % in the non-restrictive group and 3.2 % in the restrictive stoma policy group (p = 0.54). The use of a restrictive stoma policy based on the use of ghost ileostomy reduces the rate of diverting ileostomy in patients with ovarian cancer after colorectal resection and anastomosis. Furthermore, this policy is not associated with an increased rate of anastomotic leakage nor with an increased rate of morbi-mortality related to the leak.

Sections du résumé

BACKGROUND BACKGROUND
The incidence of anastomotic leak after colorectal anastomosis in ovarian cancer has been reported to be much lower than that in colorectal cancer patients. Regarding the use of protective manoeuvres (diverting ileostomy) as suggested by clinical guidelines, the goal should be the implementation of a restrictive stoma policy for ovarian cancer patients, given the low rate of anastomotic leakage in this population.
MATERIAL AND METHODS METHODS
Patients who underwent cytoreduction surgery in a single centre (University Hospital La Fe, Valencia Spain) due to ovarian cancer between January 2010 and June 2023 were classified according to two groups: a non-restrictive stoma policy group (Group A) and a restrictive stoma policy group (Group B).
RESULTS RESULTS
A total of 256 patients were included in the analysis (group A 52 % vs group B 48 %). The use of protective diverting ileostomy was lower in the restrictive stoma policy group (14 % vs 6.6 %), and the use of ghost ileostomy was 32 % vs 87 % in groups A and B, respectively (p < 0.00001). No differences were found in the anastomotic leak rate, which was 5.2 % in the non-restrictive group and 3.2 % in the restrictive stoma policy group (p = 0.54).
CONCLUSION CONCLUSIONS
The use of a restrictive stoma policy based on the use of ghost ileostomy reduces the rate of diverting ileostomy in patients with ovarian cancer after colorectal resection and anastomosis. Furthermore, this policy is not associated with an increased rate of anastomotic leakage nor with an increased rate of morbi-mortality related to the leak.

Identifiants

pubmed: 38636248
pii: S0748-7983(24)00377-9
doi: 10.1016/j.ejso.2024.108325
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108325

Informations de copyright

© 2024 Elsevier Ltd, BASO ∼ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest We declare not to have any conflict of interest.

Auteurs

Víctor Lago (V)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain; CEU Cardenal Herrera University, Valencia, Spain. Electronic address: victor.lago.leal@hotmail.com.

Manel Montesinos Albert (MM)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Marta Arnaez Cruz (MA)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Rafael Alberto Guijarro Campillo (RA)

University Hospital La Arrixaca, Murcia, Spain.

Pablo Padilla-Iserte (P)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Luis Matute (L)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Marta Gurrea (M)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Blas Flor (B)

Colorectal Surgery Unit, University Hospital La Fe, Valencia, Spain.

Santiago Domingo (S)

Gynecologic Oncology Unit, University Hospital La Fe, Valencia, Spain.

Classifications MeSH